In this episode of Post-Scrip, Henry introduces Monet Stanford, PharmD. Henry and Monet dive into The Transition of Biosimilar: From Provider-Administered to Pharmacy-Dispensed.
The biosimilars industry, which started with the first approval in 2015, is at an inflection point. In the U.S., biosimilars could lead to over $130 billion is savings by 2025, and have been used in over 364 million days of patient therapy. Until this year, most biologics — and, until adalimumab , all non-insulin biosimilars — are administered by a licensed provider in a healthcare setting and covered under Medicare Part B or the medical benefit of commercial plans.
To learn more information about Monet : https://accessiblemeds.org/about/our-team/monet-stanford
Join us at the 34th annual conference: Developments in Pharmacy Law Seminar , November 2-5, 2023 in San Antonio, Texas